Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, discussed how the FDA’s approval of Rebyota for the prevention of recurrent ...
The cost savings for health plans would increase if the therapy were used after the first recurrence of Clostridioides difficile infection (CDI). A fecal microbiota–based therapy for recurrent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results